# Kisspeptin Research: Mechanism, Human Trials and the Fertility Record > Kisspeptin research from the peer-reviewed record — the KISS1R mechanism, the human LH and testosterone data, the IVF trigger trials and the fertility findings, every figure cited. From the GPR54 genetics to the intranasal route — each finding study-attributed, with the defining tachyphylaxis limitation in plain view. ## Before the details Kisspeptin research has a tidy spine. It opens with human genetics — people missing a working GPR54 receptor never finish puberty, which is how scientists learned this signal is essential. It moves to the cellular machinery — how kisspeptin makes a GnRH neuron fire. Then come the human studies: give kisspeptin and watch LH rise, in healthy men, in women who have lost their cycles, and in IVF. The headline findings are real and repeatable: LH climbs within minutes, cycles can be coaxed back, and a kisspeptin trigger matured eggs in IVF with no severe over-stimulation. The honest caveat runs alongside all of it — give the signal continuously and it fades (tachyphylaxis), so *how* it is given matters as much as *how much*. Below, each finding gets its own section, with the source attached. ## The genetics that proved the switch The foundation is human, not animal. Loss-of-function mutations in GPR54 (KISS1R) cause autosomal-recessive idiopathic hypogonadotropic hypogonadism — absent or incomplete puberty with low LH and FSH — and Gpr54-knockout mice reproduced the phenotype, together establishing kisspeptin–GPR54 signaling as essential for reproductive maturation [1]. This is why kisspeptin is called a gatekeeper of puberty: remove the receptor and the axis never starts. ## How kisspeptin fires a GnRH neuron At the cellular level the mechanism is now well drawn. Kisspeptin (applied at 100 nM) depolarized GnRH neurons by `6 ± 1 mV` and raised their firing rate by `87 ± 4%` in roughly 75% of adult GnRH neurons tested [2]. The response runs through a phospholipase-C / IP3 / intracellular-calcium cascade (the cell's internal-signal relay) that closes potassium channels and opens non-selective cation channels — the ionic events that depolarize the neuron and drive pulsatile GnRH release [2]. The receptor, KISS1R, is a Gq/11-coupled GPCR; the KNDy neurons of the arcuate nucleus are thought to be the pulse generator that paces the rhythm [2]. ## Kisspeptin in men: LH, pulse frequency and testosterone In healthy men, intravenous kisspeptin-10 produced maximal LH stimulation at a `1 µg/kg` bolus, lifting LH from `4.1` to `12.4 IU/L` at 30 minutes; continuous infusion at `1.5 µg/kg/h` raised mean LH from `5.2` to `14.1 IU/L` and increased LH pulse frequency from `0.7` to `1.0 pulses/h`, while a higher `4 µg/kg/h` infusion raised serum testosterone from `16.6` to `24.0 nmol/L` [3]. Kisspeptin-54 showed the same direction in men: a `4 pmol/kg/min` IV infusion for 90 minutes raised mean 90-minute LH to `10.8 ± 1.5` versus `4.2 ± 0.5 U/L` on saline, with smaller rises in FSH and testosterone (LH > FSH > testosterone) [8]. A head-to-head comparison found IV kisspeptin-10 and kisspeptin-54 gave comparable gonadotropin responses at matched infusion rates [9]. ## Kisspeptin fertility research: restoring cycles and triggering IVF The fertility work is where kisspeptin research is furthest along. In women with hypothalamic amenorrhea — periods lost to stress, low weight or heavy exercise — continuous IV kisspeptin-54 (`0.01–1.00 nmol/kg/h`) restored pulsatile LH secretion: LH pulses rose from `1.6` to `5.0` per 8 hours (about threefold) and pulse secretory mass rose roughly sixfold versus vehicle, though the highest dose produced tachyphylaxis over the infusion [4]. In IVF, kisspeptin offered a safer trigger. A Phase 2 randomized trial of 60 women at high risk of ovarian hyperstimulation syndrome (OHSS) used subcutaneous kisspeptin-54 (`3.2–12.8 nmol/kg`) to trigger oocyte maturation in 95% of women, **with no case of moderate, severe or critical OHSS**; the highest live-birth rate (62%) followed the `9.6 nmol/kg` dose [5]. Supporting the same axis, a study of 50 unexplained-infertility women undergoing ICSI found follicular-fluid kisspeptin rose through stimulation and correlated positively with oocyte maturity and endometrial thickness [13]. ## The newest route, and the field map In 2025, kisspeptin research crossed a practical threshold: intranasal kisspeptin-54 (primary dose `12.8 nmol/kg`) rapidly stimulated LH release in healthy men (`+4.4 IU/L`), healthy women (`+1.4 IU/L`) and women with hypothalamic amenorrhea (`+4.4 IU/L`) without adverse events, and the nasal-spray formulation stayed stable up to 60 days at 4 °C — the first clinical demonstration of an effective non-invasive route [6]. Zooming out, a 2025 systematic review mapped 29 interventional trials spanning amenorrhea, puberty regulation, ovarian function, trophoblast invasion, fertility regulation, parturition and lactation, and noted comparatively few side effects — while confirming that no kisspeptin product is regulatory-approved [7]. The same KNDy circuitry sits at the center of functional hypothalamic amenorrhea, where stress, disordered eating and low body weight suppress GnRH pulsatility and lower LH and estradiol [14], and kisspeptin is among the markers proposed to help distinguish that condition from polycystic ovary syndrome, pending further study [15]. --- A noir reading of the Kisspeptin record — one upstream signal traced from KISS1 to GnRH and logged where the trials confirm it, the brief KP-10 flare set apart from the longer KP-54 burn, the fading-with-overuse and not-approved, not-a-supplement truths held in the light; no clinic behind the pulse, and nothing here dosed, dispensed, or sold.